These data confirm that LATS1 and LATS2 are highly expressed in IM-resistant CML patient at both mRNA and protein levels and up-regulation of LATS1 and LATS2 might be involved, at least in part, in the pathogenesis of CML. The gene discussed is LATS2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.